Ionis Pharmaceuticals (IONS)
(Delayed Data from NSDQ)
$51.45 USD
-0.41 (-0.79%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $51.42 -0.03 (-0.06%) 5:14 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
IONS 51.45 -0.41(-0.79%)
Will IONS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for IONS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IONS
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Should You Buy?
Ionis (IONS) Up 6% on Detailed Data From Angelman Drug Study
IONS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is AstraZeneca (AZN) a Portfolio Must-Have Pre-Q2 Earnings?
Ionis (IONS) Completes Enrolment for Rare Disease Drug Study
AstraZeneca (AZN) Stock Rises 18% YTD: Should You Buy?
Other News for IONS
Leerink upgrades Ionis to outperform, cites Angelman drug
Tesla downgraded, Spotify upgraded: Wall Street's top analyst calls
Ionis Pharmaceuticals just upgraded at Leerink, here's why
TD Cowen Keeps Their Buy Rating on Ionis Pharmaceuticals (IONS)
Ionis Pharmaceuticals price target raised by $1 at BofA, here's why